Lumos Pharma Statistics
Total Valuation
Lumos Pharma has a market cap or net worth of $11.85 million. The enterprise value is -$10.81 million.
| Market Cap | 11.85M |
| Enterprise Value | -10.81M |
Important Dates
The next estimated earnings date is Wednesday, August 7, 2024, after market close.
| Earnings Date | Aug 7, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Lumos Pharma has 8.12 million shares outstanding. The number of shares has decreased by -1.64% in one year.
| Shares Outstanding | 8.12M |
| Shares Change (YoY) | -1.64% |
| Shares Change (QoQ) | +0.12% |
| Owned by Insiders (%) | 34.83% |
| Owned by Institutions (%) | 26.93% |
| Float | 5.31M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 7.77 |
| Forward PS | n/a |
| PB Ratio | 0.68 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.24, with a Debt / Equity ratio of 0.03.
| Current Ratio | 6.24 |
| Quick Ratio | 5.29 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -119.90% and return on invested capital (ROIC) is -219.64%.
| Return on Equity (ROE) | -119.90% |
| Return on Assets (ROA) | -85.90% |
| Return on Capital (ROIC) | -219.64% |
| Revenue Per Employee | $46,212 |
| Profits Per Employee | -$1.13M |
| Employee Count | 33 |
| Asset Turnover | 0.04 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -29,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -54.38% in the last 52 weeks. The beta is 0.30, so Lumos Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.30 |
| 52-Week Price Change | -54.38% |
| 50-Day Moving Average | 2.27 |
| 200-Day Moving Average | 2.90 |
| Relative Strength Index (RSI) | 20.54 |
| Average Volume (20 Days) | 36,406 |
Short Selling Information
The latest short interest is 294,740, so 3.63% of the outstanding shares have been sold short.
| Short Interest | 294,740 |
| Short Previous Month | 298,004 |
| Short % of Shares Out | 3.63% |
| Short % of Float | 5.55% |
| Short Ratio (days to cover) | 26.39 |
Income Statement
In the last 12 months, Lumos Pharma had revenue of $1.53 million and -$37.13 million in losses. Loss per share was -$4.59.
| Revenue | 1.53M |
| Gross Profit | 1.53M |
| Operating Income | -39.44M |
| Pretax Income | -37.16M |
| Net Income | -37.13M |
| EBITDA | -37.12M |
| EBIT | -37.16M |
| Loss Per Share | -$4.59 |
Balance Sheet
The company has $23.18 million in cash and $518,000 in debt, giving a net cash position of $22.66 million or $2.79 per share.
| Cash & Cash Equivalents | 23.18M |
| Total Debt | 518,000 |
| Net Cash | 22.66M |
| Net Cash Per Share | $2.79 |
| Equity (Book Value) | 17.44M |
| Book Value Per Share | 2.15 |
| Working Capital | 23.13M |
Cash Flow
| Operating Cash Flow | -34.79M |
| Capital Expenditures | n/a |
| Free Cash Flow | -34.79M |
| FCF Per Share | -$4.29 |
Margins
Gross margin is 100.00%, with operating and profit margins of -2,586.30% and -2,434.69%.
| Gross Margin | 100.00% |
| Operating Margin | -2,586.30% |
| Pretax Margin | -2,436.59% |
| Profit Margin | -2,434.69% |
| EBITDA Margin | -2,434.16% |
| EBIT Margin | -2,436.59% |
| FCF Margin | -2,281.44% |
Dividends & Yields
Lumos Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 1.64% |
| Shareholder Yield | 1.64% |
| Earnings Yield | -313.32% |
| FCF Yield | -293.60% |
Analyst Forecast
The average price target for Lumos Pharma is $18.00, which is 1,132.88% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $18.00 |
| Price Target Difference | 1,132.88% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | 142.21% |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on March 19, 2020. It was a reverse split with a ratio of 1:9.
| Last Split Date | Mar 19, 2020 |
| Split Type | Reverse |
| Split Ratio | 1:9 |
Scores
Lumos Pharma has an Altman Z-Score of -11.23 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -11.23 |
| Piotroski F-Score | 3 |